The Clinical Pharmacokinetics of Cladribine
- 1 February 1997
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 32 (2), 120-131
- https://doi.org/10.2165/00003088-199732020-00003
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Oral 2‐chlorodeoxyadenosine in psoriaticArthritis & Rheumatism, 1995
- Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugsAnti-Cancer Drugs, 1995
- Analysis of 2-Chloro-2'-Deoxyadenosine in Human Blood Plasma and Urine by High-Performance Liquid Chromatography Using Solid-Phase ExtractionTherapeutic Drug Monitoring, 1994
- Cladribine in treatment of chronic progressive multiple sclerosisThe Lancet, 1994
- The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia.1994
- CladribineDrugs, 1993
- 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.Journal of Clinical Oncology, 1993
- Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of ?first-pass? metabolismEuropean Journal of Clinical Pharmacology, 1992
- A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.Journal of Clinical Oncology, 1991
- Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.Proceedings of the National Academy of Sciences of the United States of America, 1980